TGIA
FATE icon

Torrey Growth & Income Advisors’s Fate Therapeutics FATE Stock Holding History

Torrey Growth & Income Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-67,522
Closed -$85.1K – 121
2025
Q3 		$85.1K Buy
+67,522
New +$72.8K 0.03% 122

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Torrey Growth & Income Advisors's FATE Position: Q4 2025 in Review

Torrey Growth & Income Advisors sold out of Fate Therapeutics (FATE) in Q4 2025, closing a stake of 67,522 shares — an estimated $85.1K sold.

Torrey Growth & Income Advisors first reported a position in FATE in Q3 2025 and held it in 1 quarter. The position peaked at $85.1K in Q3 2025. 146 funds tracked by Wall St. Rank hold FATE as of Q4 2025.

  • Torrey Growth & Income Advisors reported no remaining Fate Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Torrey Growth & Income Advisors sold 67,522 Fate Therapeutics shares in Q4 2025, an estimated $85.1K.
  • Torrey Growth & Income Advisors first reported a position in Fate Therapeutics in Q3 2025 and held it in 1 quarter.
  • Torrey Growth & Income Advisors's Fate Therapeutics position peaked at $85.1K in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2025.

Based on Torrey Growth & Income Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.